Artelo Biosciences, a clinical-stage pharmaceutical company focused on modulating lipid-signalling pathways to develop treatments for people living with cancer, pain, and neurological conditions, has entered into a second collaboration with Richard K. Porter, Ph.D., of the School of Biochemistry & Immunology at Trinity College Dublin.
Prof. Porter’s focus will be on investigating the molecular basis of fatty acid binding protein (FABP) inhibition in cancer and the potential of the ART26.12 platform for the treatment of various tumours.
Artelo believes the research initiative will refine and expand the company’s understanding of the role of certain FABP inhibitors and could conceivably translate into multiple compounds tailored to specific cancers from Artelo’s library of compounds.
Prof. Richard Porter said:
The potential role and implications of FABP inhibition in different forms of cancer is emerging as a very exciting and promising advancement in cancer research. This collaboration with Artelo will further elucidate the specific mechanisms by which targeted FABP inhibition may prevent tumour growth and halt its spreading.
FABP plays an important role in lipid signalling and is believed to be an attractive target for cancer drug development.
Andrew Yates, Ph.D., Artelo Biosciences’ Chief Science Officer, said:
Large amounts of human biomarker and animal model data support FABP as an oncology target. We believe the evidence to date suggests inhibition of FABP may be relevant in a number of different cancers with high unmet need. We are pleased to be working on a second research project with Professor Porter, who has more than 30 years experience in metabolism and bioenergetics. The research is expected to have multiple data readouts over the next twelve months.